RPMB predicts the disease-free survival of head-and-neck squamous carcinoma after adjuvant concurrent radio-chemotherapy.

ABSTRACT:

Purpose

Currently, adjuvant concurrent radio-chemotherapy (ACRT) is the standard of care for head-and-neck squamous cell carcinoma (HNSC) with microscopically involved surgical margins (MISM) and/or extra-nodal extension (ENE), whereas the toxicity of cisplatin-based chemotherapy is non-negligible.

Methods

In the current study, we identified a novel biomarker, referred to as RPMB (Repair Gene Promoter Methylation Burden), with the aim of identifying the subset of HNSC patients who are likely to respond favorably to ACRT. RPMB is defined as the proportion of methylated DNA repair genes (DRGs) relative to the total number of DRGs. We obtained the methylation profiles and clinical data for 528 HNSC patients from the Cancer Genome Atlas (TCGA) database.

Results

Analysis r

SUBMITTER: An N 

PROVIDER: S-EPMC12187736 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature